Agent for treating retinopathy
AssigneeCarna Health Support Ltd.
InventorsToyoshi INOGUCHI, Yasutaka MAEDA, Toshinobu MAKI, Noriyuki SONODA
Life of this patent
Estimating the term…
Abstract
It is to provide an agent for treating and/or ameliorating retinopathy caused by glucose. It is an agent for treating retinopathy caused by glucose comprising sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, and is used at a normal dosage amount, or at a lower dosage whereby no lowering in blood sugar is observed.
Claims22
A composition for treating retinopathy caused by glucose, comprising sodium/glucose co-transporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, wherein the composition contains the SGLT2 inhibitor at a concentration for administration at a low dosage so that no lowering in blood sugar is observed upon administration.
(canceled)
4-8. (canceled)
A method for treating retinopathy caused by glucose, comprising administering to a patient in need thereof a composition containing sodium/glucose co-transporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, wherein the SGLT2 inhibitor is administered at a dosage so that no lowering in blood sugar is observed upon administration.
A method for treating a patient having retinopathy caused by glucose, comprising administering to the patient a composition containing sodium/glucose co-transporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, to therapeutically treat the retinopathy caused by glucose without showing an antihyperglycemic action.
Dependencies are inferred from the claim text.